



125  
FEB 14 1991  
GROUP 120

5/6  
JLT  
2/14/91

12-C

MERZ 16/dlk

CERTIFICATE OF MAILING  
UNDER 37 CFR 1.8 (a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on February 7, 1991  
GORDON W. HUBSCHEN, Attorney.

Applicant : Joachim Bormann, et al.  
Serial No. : 07/508,109  
Filed : April 11, 1990  
Title : ADAMANTANE-DERIVATIVES IN THE PREVENTION AND  
TREATMENT OF CEREBRAL ISCHEMIA  
Art Unit : 125  
Examiner : T. Wilson

Shane L. Kilken  
2-7-91

\*\*\*\*\*

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

RESPONSE AND AMENDMENT UNDER 37 CFR 1.111 AND 1.115

Sir:

Responsive to the Office Action dated January 15, 1991, kindly  
amend as follows:

IN THE CLAIMS:

Claim 10, line 1: Cancel "prevention".  
line 2: Cancel "or".

R E M A R K S

Claim 10 has been amended to remove the 35 USC 101 objection  
thereto by the Examiner as set forth on page 2 of the Office  
Action.

Claim 10 has also been rejected as unpatentable over EPA  
0227410 (Reference L) on a basis that this Reference teaches that  
"adamantane derivatives may be used to treat Alzheimer's disease  
and Alzheimer dementia". The Examiner has directed the applicants'  
attention to several portions of the disclosure of Reference L.